Composition containing lactic acid bacteria

By isolating and identifying animal Lactobacillus from healthy dog ​​feces and using it in mouse models, it was found that it has a higher inhibitory effect on atopic dermatitis and allergic asthma, which solved the lack of effect on inhibiting allergic in the prior art. The clear problem achieved significant allergic symptoms reduction and cytokine production decreased.

CN115243567BActive Publication Date: 2024-12-06SCHOOL CORP AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180019029.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-03-06
Filing Date
2021-03-05
Publication Date
2024-12-06
Estimated Expiration
2041-03-05

AI Technical Summary

Technical Problem

In the prior art, the effect of lactic acid bacteria on inhibiting allergic diseases is not clear enough, especially the fact that it is not possible to determine which bacterial species are more effective in inhibiting allergic diseases.

Method used

Lactobacillus animalis was isolated and identified from the feces of healthy dogs, and was administered orally in a mouse model. Its inhibitory effect on atopic dermatitis and allergic asthma was observed, and it was found that it was BJP's milk Bacillus (L.johnsonii) has a higher allergy inhibitory effect.

Benefits of technology

Lactobacillus animal significantly reduced allergic skin symptoms, lymph node cell count and inflammatory cytokine production, providing a higher allergic inhibitory effect than previously reported lactic acid bacteria.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003832351900000011
    Figure HDA0003832351900000011
  • Figure HDA0003832351900000012
    Figure HDA0003832351900000012
  • Figure HDA0003832351900000021
    Figure HDA0003832351900000021
Patent Text Reader

Abstract

The present invention aims to provide a composition containing lactic acid bacteria that is effective in inhibiting the onset of allergies. More specifically, the present invention is a composition containing lactic acid bacteria belonging to animal Lactobacillus, and the composition is provided as, for example, a pharmaceutical composition, a feed composition, and a sanitary composition. Furthermore, the present invention provides a method for preventing the onset of allergies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a composition containing lactic acid bacteria having an anti-allergic effect. Background Art

[0002] The onset of allergic diseases is controlled by the interaction of various factors such as genetic factors and environmental factors (eg, the growth environment during infancy and childhood, intestinal flora, etc.).

[0003] It is believed that intestinal bacteria affect the development of the host's immune system (non-patent document 1), and lactic acid bacteria can be cited as intestinal bacteria that have a certain relationship with allergic diseases. In addition, there are also reports that the environment in which pets live during infancy is important as an environmental factor for allergic diseases. For example, the microbial crosstalk between humans and pets produced by contact with pets (dogs, cats, etc.) during infancy can inhibit allergic attacks (non-patent documents 2 and 3). Fujimura et al. reported that the ratio of lactic acid bacteria Lactobacillus Johnsonii in the intestinal flora of mice exposed to house dust in an environment where dogs are raised increased significantly, and Lactobacillus Johnsonii plays an important role in inhibiting allergic respiratory diseases (non-patent document 4).

[0004] On the other hand, Taylor et al. administered Lactobacillus acidophilus to infants born to mothers with allergic diseases until 6 months after birth to analyze the effect of lactic acid bacteria on allergic attacks. The results showed that at 1 year old, there was no significant difference in the incidence of atopic dermatitis between the treatment group and the placebo group, and the positive rate of IgE antibodies was higher in the Lactobacillus acidophilus group (Non-Patent Document 5).

[0005] As shown above, lactic acid bacteria have a certain effect on allergic diseases, but it shows opposite results (non-patent document 5 is a negative result, non-patent document 4 is a positive result). Further analysis is needed to determine which strains are more effective and practical in inhibiting allergies.

[0006] Prior art literature

[0007] Non-patent literature

[0008] Non-patent document 1: Macphers and Harris, Nat Rev Immunol. 4: 478-485 2004.

[0009] Non-patent document 2: Hesselmar et al., Clin Exp Allergy. 29: 611-617 1999.

[0010] Non-patent document 3: Fall et al., JAMA Pediatr. 169e153219 2015

[0011] Non-patent document 4: Fujimura et al., Proc Natl Aca Sci USA 14:805-810 2014.

[0012] Non-patent document 5: Tylor et al., J Allergy Clin Immuno. 119: 184-191 2007. Summary of the invention

[0013] In view of the above circumstances, an object of the present invention is to provide a composition containing lactic acid bacteria which is effective in suppressing the onset of allergies.

[0014] The inventors of the present invention believe that the intestinal bacteria of dogs have some effects on the host's immune system, and compared the intestinal flora of healthy dogs with that of atopic dogs, and selected the bacteria that are dominant in healthy dogs. Specifically, among the 240 strains isolated from the feces of healthy dogs, 184 strains belong to the above-mentioned selected bacteria, and these bacteria were subjected to a systematic classification analysis based on the 16sRNA gene. As a result, 13 species of 4 genera of the genera Bacteroides, Enterococcus, Lactobacillus and Streptococcus were identified, among which Lactobacillus animalis (L.animalis), which has not been reported to be related to allergic attacks, was used as the analysis object.

[0015] The inventors of the present invention observed the effect of suppressing various symptoms caused by allergies when orally administering animal lactobacillus to atopic dermatitis model and allergic asthma model of mice. It was also found that animal lactobacillus showed a higher allergy suppressing effect than Lactobacillus johnsonii, which was previously reported to have an allergy suppressing effect.

[0016] The present invention has been accomplished based on the above findings.

[0017] That is, the present invention relates to the following (1) to (7).

[0018] (1) A composition comprising lactic acid bacteria belonging to Lactobacillus animalis or a processed product thereof.

[0019] (2) The composition according to (1) above, wherein the lactic acid bacteria are Lactobacillus animalis strains deposited under the accession number NITE BP-03137, the accession number NITE BP-03138, the accession number NITE BP-03139 and / or the accession number NITE BP-03140.

[0020] (3) The lactic acid bacteria or the composition according to (1) or (2) above, which has antiallergic activity.

[0021] (4) The composition according to any one of (1) to (3) above, which is a pharmaceutical composition.

[0022] (5) The composition according to any one of (1) to (3) above, which is a feed composition.

[0023] (6) The composition according to any one of (1) to (3) above, wherein the composition is a sanitary composition.

[0024] According to the present invention, it is possible to provide a lactic acid bacteria strain that exhibits a higher allergy-suppressing effect than conventionally reported lactic acid bacteria strains. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 The results of the analysis using the atopic dermatitis model (1) are shown. The number of scratching behaviors of the model mice was measured every hour 4 weeks (A) and 7 weeks (B) after the start of transdermal administration of mite antigens (n=8). The data represent the mean, and the error bars represent the standard error. **P<0.01.

[0026] Figure 2 The results of the analysis using the atopic dermatitis model (2) are shown. The skin symptoms were scored weekly from the start of transdermal administration of mite antigens until 10 weeks (left figure) (n=8). The data represent the mean value, and the error bars represent the standard error. In addition, a photograph of the skin symptoms of the model mice after administration of mite antigens is shown (right figure).

[0027] Figure 3 The results of the analysis using the atopic dermatitis model (3) are shown. The thickness of the back skin was measured weekly from the start of transdermal administration of the mite antigen to 10 weeks (n=8). The data represent the mean, and the error bars represent the standard error. **P<0.01, *P<0.05.

[0028] Figure 4 The results of the analysis using the atopic dermatitis model (4) are shown. CD3 + CD4 + T cells (A), CD19 + IgE + B cells (B) and CD11c + CD40 +The results were obtained by measuring the number of dendritic cells (C) (n=8). Data represent mean values, and error bars represent standard errors. **P<0.01, *P<0.05. Intact is the result of using mice that were not treated with mites, and Control is the result of using model mice that were not administered with lactic acid bacteria (the same in the following figures).

[0029] Figure 5 The results of the analysis using the atopic dermatitis model (5) are shown. The amounts of various cytokines (A: IL-4, B: IL-9, C: IL-13, D: IL-17, E: TNFα) produced in the auricular lymph nodes collected from the model mice on the day following the final administration of the mite antigen were measured (n=8). ND is below the detection limit. The data represent the mean value, and the error bars represent the standard error. **P<0.01, *P<0.05.

[0030] Figure 6 The results of the analysis using the atopic dermatitis model (6) are shown. The amounts of various cytokines (A: IL-1α, B: IL-4, C: IL-5, D: IL-9, E: IL-13, F: IL-17) produced in the auricle skin tissue collected from the model mice on the day after the final administration of the mite antigen were measured (n=8). The data represent the mean value, and the error bars represent the standard error. **P<0.01, *P<0.05.

[0031] Figure 7 The results of the analysis using the atopic dermatitis model (7) are shown. The amounts of various cytokines (A: IL-33, B: TNFα, C: TSLP) produced in the auricle skin tissue collected from the model mice on the day after the final administration of the mite antigen were measured (n=8). The data represent the mean, and the error bars represent the standard error. *P<0.05.

[0032] Figure 8 The results of analysis using an atopic dermatitis model are shown (8). Serum was prepared from blood collected from model mice on the day following the final administration of mite antigens, and the total IgE content in the serum was measured (n=8). Error bars indicate standard errors.

[0033] Fig. 9 The results of the analysis using the allergic asthma model (1) are shown. CD3 + CD4 + T cells (A), CD19 + IgE + B cells (B) and CD11c + CD40 +The results were obtained by comparing the number of dendritic cells (C) (n=8). Data represent mean values, and error bars represent standard errors. **P<0.01, *P<0.05.

[0034] Fig.10 The results of the analysis using the allergic asthma model (2) are shown. The amounts of various cytokines (A: IL-4, B: IL-5, C: IL-9, D: IL-13, E: IL-17) produced in the hilar lymph nodes collected from the model mice on the day following the final induction of the mite antigen were measured (n=8). ND is below the detection limit. The data represent the mean, and the error bars represent the standard error. **P<0.01, *P<0.05.

[0035] Fig.11 The results of the analysis using the allergic asthma model (3) are shown. The results are obtained by counting the eosinophils (A) and neutrophils (B) in the alveolar lavage fluid collected from the model mice on the day after the final induction of the mite antigen (n=8). The data represent the mean, and the error bars represent the standard error. **P<0.01, *P<0.05. DETAILED DESCRIPTION

[0036] A first embodiment of the present invention is a composition containing lactic acid bacteria belonging to Lactobacillus animalis or a processed bacterial cell thereof (hereinafter also referred to as "the composition of the present invention"). As animal lactobacillus used in an embodiment of the present invention, for example, in addition to the strain whose gene sequence is registered with NCBI accession number NZ_AYYW00000000.1, it is preferred that the strains specified by the deposit number NITE P-03137 (identification name: L11-2), deposit number NITE P-03138 (identification name: L13-1), deposit number NITE P-03139 (identification name: L41-1) and deposit number NITE P-03140 (identification name: M08-1) are deposited at the Patent Microorganism Depository (NPMD) of the Biotechnology Center of the Institute of Technology for Product Evaluation, Japan on February 21, 2020 (original deposit date) (postal code 292-0818, 2-5-8, Kazusa Kamata, Kisarazu-shi, Chiba Prefecture, Japan). It should be noted that the strains specified by deposit number NITE P-03137, deposit number NITE P-03138, deposit number NITE P-03139 and deposit number NITE P-03140 were subsequently transferred from the original depository to the international depository based on the Budapest Treaty (the date of issuance of the "deposit certificate of the original deposit" and the "survival certificate": March 4, 2021), and the deposit numbers are deposit number NITE BP-03137, deposit number NITE BP-03138, deposit number NITE BP-03139 and deposit number NITE BP-03140 respectively. The above deposited strains can be obtained from the above depository institutions.

[0037] The method for culturing animal Lactobacillus is not particularly limited, and any method may be used as long as it is a method commonly selected by those skilled in the art as a method for culturing lactic acid bacteria. For example, the culture temperature may be 20 to 50°C, preferably 25 to 40°C, under anaerobic conditions.

[0038] The substratum that is used for the breeding of animal lactobacillus is not particularly limited, and the substratum that those skilled in the art select usually can be used.As such substratum, for example, as long as for being applicable to the substratum that contains following composition of bacterial classification: carbon source (glucose, galactose, mannose, lactose, sucrose, cellobiose, trehalose etc.), nitrogen source (ammonia, ammonium sulfate, ammonium chloride, ammonium nitrate etc.), inorganic salts (sodium chloride, potassium chloride, potassium sulfate, magnesium sulfate, calcium chloride, calcium nitrate etc.), organic component (peptone, yeast extract, meat extract, soy flour etc.), can preferably use MRS substratum, LBS substratum etc.

[0039] As the processed bacterial body material of the present invention, for example, bacterial culture and fermentation products can be cited, and the state of the lactic acid bacteria contained therein can be any state of live bacteria or dead bacteria. In addition, as the processed bacterial body material, for example, materials obtained by heating, paste, drying, freezing, lysing, crushing, extracting, etc. of lactic acid bacteria, supernatants obtained by removing solid components of crushed bacterial bodies, bacterial cultures, and fermentation products, etc. can be cited, but are not limited to these.

[0040] In addition, in the composition of the present invention, other substances can be contained except animal lactobacillus or its processed bacterial cell. As other substances, there is no particular restriction, for example, lactose, glucose, mannitol, sucrose, dextrin, cyclodextrin, starch, cellulose, collagen, citric acid, acetic acid, salt, vitamins etc. can be contained.

[0041] The composition of the present invention has an effect of suppressing the onset of allergies, and can be provided, for example, as a pharmaceutical composition, a feed composition, a sanitary composition, etc., depending on the purpose of use, but is not limited to these compositions.

[0042] When the composition of the present invention is a pharmaceutical composition, its dosage form is not particularly limited, for example, tablets, capsules, granules, powders, syrups, liquid preparations, suppositories or injections can be cited. These preparations can be prepared according to conventional methods. In addition, in the case of liquid preparations, they can be dissolved or suspended in water or other appropriate solvents when used. In addition, tablets and granules can be coated with known methods. In the case of injections, the antibody of the present invention or its functional fragment can be prepared by being dissolved in water, and can be dissolved in physiological saline or glucose solution as needed, and a buffer and a preservative can be added.

[0043] When the composition of the present invention is provided as a sanitary composition, its form is not particularly limited, and it can be, for example, toothpaste, skin cream, soap, shampoo, cosmetics, aerosol, spray, coating, etc. It can also be a sanitary composition for non-human animals.

[0044] In addition, the composition of the present invention may be a feed composition that can be ingested by non-human animals and a pharmaceutical composition for animals. The animal feed mentioned here includes not only food ingested as a nutrient source required by animals, but also supplements for animals given as a hobby of animals.

[0045] A second embodiment of the present invention is a method for preventing the onset of allergies (hereinafter also referred to as "the prevention method of the present invention"), comprising administering the pharmaceutical composition of the present invention to a subject.

[0046] Here, "prevention" refers to treatment aimed at preventing the occurrence of allergies in advance.

[0047] The subject of the prevention method of the present invention is not particularly limited, and may be any animal classified as a mammal, for example, in addition to humans, pets such as dogs, cats, rabbits, and livestock such as cows, pigs, sheep, and horses, etc. Particularly preferred "mammals" are humans and dogs.

[0048] In the case where this specification is translated into English and includes words in the singular form of “a”, “an”, and “the”, both the singular and plural cases are included unless explicitly stated otherwise in the text.

[0049] The present invention will be further described below with reference to Examples. However, these Examples are merely illustrative of the embodiments of the present invention and do not limit the scope of the present invention.

[0050] Example

[0051] 1. Experimental Methods

[0052] 1-1. Isolation and classification of lactic acid bacteria from feces

[0053] Among the 240 strains of bacteria isolated from the feces of healthy dogs (16 dogs), 184 strains that were dominant in the intestinal flora of healthy dogs compared with the intestinal flora of atopic dogs were selected for systematic classification analysis. Specifically, the feces collected from the dogs were cultured overnight at 37°C under anaerobic conditions using MRS liquid culture medium or LBS liquid culture medium. After culture, the bacteria were separated using MRS or LBS plate culture medium. Purification was performed at least 3 times. The systematic classification of bacteria was based on 16SrRNA sequencing. As a result, 13 species of 4 genera of Bacteroides, Enterococcus, Lactobacillus and Streptococcus were identified, from which Lactobacillus animalis (L.animalis) of the genus Lactobacillus, which has not been reported to be associated with allergic attacks, was selected as the object of analysis. It should be noted that as a positive control in this embodiment, Lactobacillus johnsonii (L.johnsonii), which is believed to be associated with allergic attacks, was used. The animal Lactobacillus used in this example is a mixture of strains deposited under the deposit numbers NITE BP-03137, NITE BP-03138, NITE BP-03139 and NITE BP-03140 at a bacterial count ratio of 1:1:1:1.

[0054] 1-2. Analysis using disease model mice

[0055] All animal experiments used in this example were performed with the approval of the Animal Experiment Committee of Azabu University.

[0056] 1-2-1. Atopic dermatitis model

[0057] The experiment was conducted using 6-week-old female NC / Nga mice (Charles River Laboratories Japan Co., Ltd.). After acclimation for 1 week, each mouse was orally administered 0.2 ml (10 9 ) 2 weeks later, sensitization with mite antigen (Dermatophagoides farinae) was started. Before sensitization with mite antigen, the skin on the back of the neck was shaved, and after 10 times of tape stripping on the back of the neck, 30 μl (0.25 mg / ml) of mite suspension was transdermally administered to each of the two auricles using a pipette. The administration of mite antigen was carried out twice a week for 12 weeks, and the monitoring of itching behavior, scoring of skin symptoms, and thickness measurement of the back skin were carried out every week.

[0058] The monitoring of itch behavior was performed by recording the behavior of mice with a video camera. Biting or scratching the mite antigen-applied site (auricle and back skin) with the hind limbs, forelimbs or tongue was regarded as one itch behavior, and the number of itch behaviors within 60 minutes was recorded.

[0059] In skin observation, the formation of crusts and ulcers and redness of the auricle and back skin were scored (the degree of the symptoms was scored on a scale of 0 to 4), and the cumulative value was evaluated as a cumulative score.

[0060] The thickness of the back skin was measured once a week using a vernier caliper.

[0061] On the day following the final administration of the mite antigen, blood was collected from the mice under isoflurane inhalation anesthesia, and the mice were euthanized and the auricular lymph nodes and auricular skin were sampled.

[0062] After separating serum from blood, the total IgE amount in the blood was quantified by ELISA.

[0063] After single cell isolation, the auricular lymph nodes were separated and the cells were obtained based on cell surface antigens using flow cytometry. The helper T cells (CD3 + CD4 + T cells) were cultured in the presence of anti-CD3 antibody and anti-CD28 antibody (VERITAS Corporation) for 24 to 96 hours, and the production of various cytokines in the culture supernatant was measured by ELISA.

[0064] The collected auricle skin was frozen with liquid nitrogen, homogenized in 500 μl of PBS using an electric homogenizer, and the amounts of various cytokines in the supernatant were measured by the ELISA method.

[0065] 1-2-2. Allergic asthma model

[0066] The experiment was conducted using 6-week-old female BALB / c mice (Charles River Laboratories Japan Co., Ltd.). After acclimation for 1 week, each mouse was orally administered 0.2 ml (10 9 ) After 2 weeks, sensitization with mite antigen (dust mite, Dermatophagoides farinae) was started. Sensitization with mite antigen was performed by nasal administration of 30 μl (1 mg / ml) of mite suspension using a pipette under isoflurane inhalation anesthesia. The administration of mite antigen was performed once a week for 3 consecutive weeks. Using the same method, 5 μl (0.2 mg / ml) of mite suspension was induced into the nasal cavity for 3 consecutive days in the 4th week under isoflurane inhalation anesthesia using a pipette. On the day after the final induction of mite antigen, blood was collected from the mice under isoflurane inhalation anesthesia, and then the mice were euthanized, and the hilar lymph nodes and alveolar washing fluid were sampled.

[0067] Alveolar lavage fluid is used to count the number of eosinophils and neutrophils in the lavage fluid.

[0068] Hilar lymph nodes were isolated from single cells and then separated based on cell surface antigens using flow cytometry. Helper T cells (CD3 + CD4 + After culture of WT T cells in the presence of anti-CD3 and anti-CD28 antibodies for 24 to 96 hours, the production of various cytokines in the culture supernatant was measured by ELISA.

[0069] 1-3. Statistical analysis

[0070] The mean and standard error of each group were calculated for the obtained data, and multiple comparison tests were performed in all groups for each experiment. In the multiple comparison test, the variance test was performed using the Bartlett method, etc., and in the case of variance, Dunnett's test was used. For each test item, the presence or absence of statistically significant differences between the groups was analyzed at the significance level of 5 and 1%.

[0071] 2. Results

[0072] 2-1. Atopic dermatitis model

[0073] Atopic dermatitis is a pathological condition in which itching and skin inflammation alternate and worsen symptoms. Therefore, the effect of lactic acid bacteria on itching was studied by measuring the itching behavior of a mouse model every hour immediately after weekly administration of mite antigen.

[0074] Based on the results of the analysis of a mouse model of atopic dermatitis induced by administration of mite antigens, it is believed that the number of scratching behaviors of mice administered with Lactobacillus animalis and Lactobacillus johnsonii was significantly reduced compared with control mice (no lactic acid bacteria were administered) ( Figure 1 A and B).

[0075] also, Figure 2 This is the result of scoring atopic skin symptoms during the administration of mite antigens. The manifestation of atopic symptoms varies greatly among individuals, and although no statistically significant differences were found, the degree of reduction in skin symptoms was higher in the animal Lactobacillus administration group and the Lactobacillus johnsonii administration group than in the control group. In addition, if the animal Lactobacillus administration group is compared with the Lactobacillus johnsonii administration group, the degree of symptom reduction in the animal Lactobacillus administration group is greater.

[0076] As the symptoms of atopic dermatitis worsen, epidermal thickening and cell infiltration occur, and the thickness of the skin increases. Therefore, the thickness of the back skin of the model mice was measured. As a result, the skin thickness of the animal Lactobacillus administration group and the Lactobacillus johnsonii administration group decreased significantly compared with the control group. Among them, it was observed that the thickness reduction in the animal Lactobacillus administration group was statistically significant, and even compared with the Lactobacillus johnsonii administration group, there was a significant reduction ( Figure 3 ).

[0077] After the final autopsy, the auricular lymph nodes were collected and the allergy-related immune cells (helper T cells (CD3 + CD4 + T cells), IgE-positive B cells (CD19 + IgE + B cells) and activated dendritic cells (CD11c + CD40 + The results showed that among all cells, the number of cells in the animal Lactobacillus administration group and the Lactobacillus johnsonii administration group decreased. In particular, a significant decrease was observed in helper T cells and IgE-positive B cells compared with the control group, among which the decrease in the animal Lactobacillus administration group was significant ( Figure 4 ).

[0078] Next, helper T cells collected from the auricular lymph nodes were cultured in the presence of CD3 and CD28 antibodies, and the production of inflammatory cytokines (IL-4, IL-9, IL-13, IL-17, and TNFα) was measured. The results showed that the production of any inflammatory cytokine was significantly reduced in the Lactobacillus animalis and Lactobacillus johnsonii groups compared with the control group ( Figure 5 ). In particular, a significant decrease in the production of inflammatory cytokines was observed in the group administered with Lactobacillus animalis compared to the group administered with Lactobacillus johnsonii.

[0079] The levels of inflammatory cytokines (IL-1α, IL-4, IL-5, IL-9, IL-13, and IL-17) in the auricular skin tissue were measured. Similar to the results of the auricular lymph nodes, a significant decrease in the levels of cytokines was observed in the Lactobacillus animalis-administered group and the Lactobacillus johnsonii-administered group ( Figure 6 In addition, the results of quantitative analysis of the amounts of cytokines (IL-33, TNFα, and TSLP (thymic stromal lymphopoietin)) associated with pruritus in the auricular skin tissue are shown in Figure 7 Although no significant decrease in TSLP was observed, a significant decrease in the production of keratinocyte-derived cytokines such as IL-33 and TNFα was observed in the Lactobacillus animalis-administered group and the Lactobacillus johnsonii-administered group compared with the control group.

[0080] Next, the total IgE amount in the serum prepared from the model mice was measured. As a result, a significant decrease in the total IgE amount in the serum was observed in the Lactobacillus animalis-administered group and the Lactobacillus johnsonii-administered group ( Figure 8 ).

[0081] 2-2. Allergic asthma model

[0082] After the final autopsy of the allergic asthma model mice, the hilar lymph nodes were collected, and the number of allergy-related immune cells (helper T cells, IgE-positive B cells, and activated dendritic cells) in the lymph nodes was analyzed by flow cytometry in the same manner as the atopic dermatitis model. As a result, for all allergy-related immune cells, a significant decrease in the number of each cell in the hilar lymph nodes of the animal Lactobacillus administration group and the Lactobacillus johnsonii administration group was observed. In particular, the reduction in the animal Lactobacillus administration group was significant ( Fig. 9 ).

[0083] Next, helper T cells collected from hilar lymph nodes were cultured in the presence of CD3 and CD28 antibodies, and the production of inflammatory cytokines (IL-4, IL-5, IL-9, IL-13, and IL-17) was measured. As a result, the production of any inflammatory cytokine was significantly reduced in the Lactobacillus animalis-administered group and the Lactobacillus johnsonii-administered group compared with the control group ( Fig.10 ). In particular, a significant decrease in the production of inflammatory cytokines was observed in the group administered with Lactobacillus animalis compared to the group administered with Lactobacillus johnsonii.

[0084] When the allergic asthma model mice were finally dissected, the lungs were washed with PBS, and the number of eosinophils and neutrophils in the washing fluid (alveolar washing fluid, BALF) was counted using flow cytometry ( Fig.11). For any cell species, a decrease in the number of cells was observed in both the Lactobacillus animalis-administered group and the Lactobacillus johnsonii-administered group, and a significant decrease in the number of cells was observed in the Lactobacillus animalis-administered group in particular.

[0085] Industrial Applicability

[0086] The present invention provides a composition that exhibits an effect of suppressing the onset of allergies, and is expected to be used in the field of manufacturing sanitary products in addition to the fields of medicine and veterinary medicine.

[0087] Accession number

[0088] Accession number: NITE BP-03137

[0089] Accession number: NITE BP-03138

[0090] Accession number: NITE BP-03139

[0091] Accession number NITE BP-03140.

Claims

1. A composition having antiallergic activity, wherein: Containing lactic acid bacteria belonging to animal Lactobacillus or processed bacteria thereof, The lactic acid bacteria are animal Lactobacillus strains preserved with the preservation numbers NITE BP-03137, NITE BP-03138, NITE BP-03139 and NITE BP-03140, The bacterial cell processed product is a culture or fermentation product of the bacterial cells.

2. The composition according to claim 1, wherein The composition is a pharmaceutical composition.

3. The composition according to claim 1, wherein The composition is a feed composition.

4. The composition according to claim 1, wherein The composition is a hygienic composition.